title: Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases.
abstract: We studied the efficacy and tolerance of humanized Ab interfering with the signal of the IL-2 and IL-15 receptors in a primate model of experimental autoimmune uveoretinitis. The inhibitory effects of humanized anti-Tac (HAT), an anti-IL-2R alpha-chain Ab, and HuMik beta1, an Ab directed at the beta-chain shared by the receptors of IL-2 and IL-15, were tested in culture on the proliferative response of monkey Con A-blast lymphocytes stimulated with IL-2 or IL-15. Uveitis was induced in cynomolgus monkeys by immunization with human recombinant retinal S-antigen. Treatment was initiated at the first sign of disease and consisted of HAT and HuMik beta1, alone or in combination, or vehicle control given by i.v. injection twice a week for 4 wk. Disease was evaluated by ocular funduscopy. The results in culture showed a significant dose-dependent inhibition of the IL-2-driven proliferation of lymphocytes by HAT. HuMik beta1 alone was ineffective against IL-2 stimulation, but had a marked potentiating effect in combination with HAT, independent of IL-15 signaling. IL-15-driven proliferation was inhibited by HuMik beta1, but not by HAT alone or in combination. In monkeys, experimental autoimmune uveoretinitis evolution was significantly inhibited by HAT treatment. HuMik beta1 alone had no effect on the disease. However, when used in combination, the two Ab markedly reduced the severity of ocular inflammation. The Ab were well tolerated. Only three monkeys, treated with HAT alone, made an Ab response against the injected Ab.
authors.affiliation: Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Guex-Crosier
authors.forename: J
authors.initials: J
authors.lastname: Raber
authors.forename: C C
authors.initials: CC
authors.lastname: Chan
authors.forename: M S
authors.initials: MS
authors.lastname: Kriete
authors.forename: J
authors.initials: J
authors.lastname: Benichou
authors.forename: R S
authors.initials: RS
authors.lastname: Pilson
authors.forename: J A
authors.initials: JA
authors.lastname: Kerwin
authors.forename: T A
authors.initials: TA
authors.lastname: Waldmann
authors.forename: J
authors.initials: J
authors.lastname: Hakimi
authors.forename: F G
authors.initials: FG
authors.lastname: Roberge
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D001327:Autoimmune Diseases / Q000276:immunology*; D002478:Cells, Cultured; D004195:Disease Models, Animal; D000882:Haplorhini; D006801:Humans; D008213:Lymphocyte Activation; D010446:Peptide Fragments / Q000276:immunology*; D053647:Receptors, Interleukin-15; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology*; D014605:Uveitis / Q000276:immunology* / Q000517:prevention & control
chemical_list: D000911:Antibodies, Monoclonal; C508024:IL15RA protein, human; D010446:Peptide Fragments; D053647:Receptors, Interleukin-15; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins